Mechanism of LDL Receptor Degradation by PCSK9

PCSK9 降解 LDL 受体的机制

• 批准号: 304572
• 负责人: Lagace Thomas A
• 金额: $ 39.98万
• 依托单位: University of Ottawa Heart Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-03-01 至 2019-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=304572&lang=en
• 关键词: Calcium Binding; Endocytic Receptor Recycling; Epidermal Growth Factor-Like Domains; Low-Density Lipoprotein Receptor; Proprotein Convertase Subtilisin/Kexin Type-9; Protein Degradation; Protein Trafficking; Protein-Protein Interaction

Low-density lipoprotein (LDL), the so-called "bad" cholesterol, is a major cause of heart disease and stroke. More than 25 million people worldwide take a class of drugs known as statins to help lower their LDL cholesterol level to within recommended heal

低密度脂蛋白（LDL），所谓的“坏”胆固醇，是心脏病和中风的主要原因。全世界有超过2500万人服用他汀类药物，以帮助降低他们的低密度脂蛋白胆固醇水平到推荐的范围内。